leadf
logo-loader
viewBausch Health Cos Inc

Bausch Health’s 2Q loss widens, but revenue beats Street estimates

Investors sent shares of the drugmaker up after it said it still expects full-year revenue of US$8.15bn to US$8.35bn

Bausch & Lomb product
A trio of drugs are hitting the market this year to replace sales of drugs facing stiffer competition from generics

Bausch Health Cos Inc (NYSE: BHC), formerly known as Valeant Pharmaceuticals, reported a wider-than-expected loss in the second quarter Tuesday despite beating Wall Street revenue estimates.

For the quarter ended June 2018, the well-diversified pharma company swung to a loss of US$873 mln, or US$2.49 a share, wider than the loss of US$38mln, or US$0.11 a share, posted in the year-earlier period. Revenue was approximately US$2.128bn. The consensus earnings estimate called for EPS of US$0.80 on revenue of US$2.063bn.

Investors gave the drug maker a pass after it explained that the loss was mostly due to an asset impairment linked to the loss of exclusivity on a product it didn’t name. A trio of drugs are hitting the market this year with the goal of replacing sales that are reliant on keystone drugs poised to face greater competition from generics.

As a result, shares of Bausch Health were buoyant, up over 6% to US$23.92.

All eyes were aptly focused on sales in the company’s biggest business, Bausch + Lomb which logged revenues of US$1.209bn for the second quarter, a decrease of US$14mln, or 1% compared to the same period last year. 

"The company delivered overall organic growth, driven by solid results in our Salix and Bausch + Lomb/International segments, which together represented 78% of our business in the quarter," Bausch Health CEO Joseph C Papa said in a statement.

The Canada-based company said it realigned into four reporting segments in the quarter, namely Bausch and Lomb/International, its eye treatments; Salix, its gastroenterology business; Ortho Dermatologics; and diversified products.

Bausch Health said sales of its potential blockbuster gastrointestinal drug Xifaxan grew 26% and contributed the most to the Salix segment’s US$441mln kitty.

The company said it still expects full-year revenue of US$8.15bn to US$8.35bn.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter@UttaraProactive 

Quick facts: Bausch Health Cos Inc

Price: 31.42 USD

NYSE:BHC
Market: NYSE
Market Cap: $11.17 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Bionomics' positive pharmacokinetic results confirms it can begin second...

Bionomics Limited (ASX:BNO) (OTCQB:BNOEF) Executive Chairman Errol De Souza tells Proactive tells Proactive the Adelaide, Australia- based biopharmaceutical company has received positive pharmacokinetic results from a 7-day dosing study to treat PTSD, using its new formulation of BNC210. De...

1 day, 17 hours ago

2 min read